Position in NBIX
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$12,286,228
+$471,127 QoQ
Shares Held
72,898
-18.7% QoQ
Ownership
0.072%
of shares outstanding
% of Portfolio
3.31%
of 13F equity value
Holder Rank
#144
of 774 holders
Holding Since
Dec 2022
12 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Atle Fund Management AB holds $23,463,600 across 2 Drug Manufacturers - Specialty & Generic names. NBIX ranks #1 (52.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
This page
|
72,898 | $12,286,228 | |
| 2 | ALKS |
Alkermes plc.
|
213,329 | $11,177,372 |
All Filings in NBIX
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12,286,228 | 72,898 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $11,815,101 | 89,685 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $13,444,916 | 94,796 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $1,529,451 | 102,625 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $11,109,990 | 88,392 | Shares | Sole | 2025-07-14 | |
| 2025-03-31 | $8,392,438 | 75,881 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $9,249,649 | 67,763 | Shares | Sole | 2025-02-04 | |
| 2024-09-30 | $6,983,138 | 60,607 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $3,253,142 | 23,630 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $5,996,761 | 43,480 | Shares | Sole | 2024-04-25 | |
| 2023-12-31 | $1,662,415 | 12,617 | Shares | Sole | 2024-01-30 | |
| 2022-12-31 | $22,215 | 186 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||